|
|
|
|
|
| Zanaga,L.P.; Vigani,A.G.; Angerami,R.N.; Giorgetti,A.; Escanhoela,C.A.F.; Ataíde,E.C.; Boin,I.F.S.F.; Stucchi,R.S.B.. |
| Recurrent hepatitis C after orthotopic liver transplantation (OLT) is universal and can lead to graft failure and, consequently, reduced survival. Hepatitis C treatment can be used to prevent these detrimental outcomes. The aim of this study was to describe rates of hepatitis C recurrence and sustained virological response (SVR) to interferon-based treatment after OLT and its relationship to survival and progression of liver disease through retrospective analysis of medical records of 127 patients who underwent OLT due to cirrhosis or hepatocellular carcinoma secondary to chronic hepatitis C between January 2002 and December 2013. Fifty-six patients were diagnosed with recurrent disease, 42 started interferon-based therapy and 37 completed treatment.... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C; Liver transplantation; Sustained virological response; Recurrent hepatitis C; Transplantation outcomes. |
| Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000100701 |
| |
|
|
| Zanaga,L.P.; Santos,A.G.; Ataíde,E.C.; Boin,I.F.S.F.; Stucchi,R.S.B.. |
| Recurrent hepatitis C (HCV) after liver transplantation (LT) is an important cause of morbidity and mortality. Antiviral treatment is recommended to avoid unfavorable outcomes. Direct-acting antivirals (DAA) have transformed HCV treatment, with higher efficacy and fewer side-effects than interferon-based therapies traditionally used. To evaluate DAA treatment outcomes at a Brazilian transplant unit, data of patients who finished HCV treatment at the Liver Transplant Unit of the University of Campinas were analyzed. Treatment consisted of sofosbuvir, daclatasvir, and ribavirin, for 12 or 24 weeks, according to the national guidelines. Fifty-five patients completed antiviral treatment and 54 had HCV-viral load results available. The majority of patients were... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C; Liver transplantation; Direct acting antivirals; Sofosbuvir; Daclatasvir; Recurrent hepatitis. |
| Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000800606 |
| |
|
|
| Zanaga,L.P.; Miotto,N.; Mendes,L.C.; Stucchi,R.S.B.; Vigani,A.G.. |
| Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir (DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83–100%, without significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contraindications and... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Genotype 3; Sofosbuvir; Daclatasvir; Ribavirin. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016001100302 |
| |
|
|
| Miotto,N.; Mendes,L.C.; Zanaga,L.P.; Goncales,E.S.L.; Lazarini,M.S.K.; Pedro,M.N.; Goncales Jr.,F.L.; Stucchi,R.S.B.; Vigani,A.G.. |
| The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin ≤8.5 mg/dL. We included 203 patients: 132 treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and anemia was the main... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Protease inhibitor; Anemia; Adverse events; Treatment interruption. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000700702 |
| |
|
|
|
